YANCOPOULOS GEORGE
SEC CIK 1226690 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| REGN | Regeneron Pharmaceuticals | Pres, Chief Scientific, Dir | 339.0K | — | $202.52M | 21 | 2021-06-24 | 2025-12-31 |
Most active insiders at REGN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | POON CHRISTINE A | Dir | — | $4.25M |
| 2 | McCourt Marion | EVP Commercial | — | $2.00M |
| 3 | Zoghbi Huda Y | Dir | — | $1.92M |
| 4 | Pitofsky Jason | VP Ctrl | — | $1.87M |
| 5 | Bassler Bonnie L | Dir | — | $1.77M |
| 6 | Guarini Kathryn | Dir | — | $660.0K |
| 7 | RYAN ARTHUR F | Dir | — | $434.7K |
| 8 | MURPHY ANDREW J | EVP Research | — | — |
| 9 | Fenimore Christopher R. | EVP Fin CFO | — | — |
| 10 | Schenkein David P | Dir | — | — |
| 14 | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | — | — |
Transactions 21
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-05 | 2025-12-31 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | M - OptEx | $0.00 | +28.6K | 339.0K | +9% | $0 |
| D | 2026-01-05 | 2025-12-31 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | F - Tax | $772.09 | -28.6K | 310.5K | -8% | -$22.06M |
| D | 2025-12-11 | 2025-12-09 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | M - OptEx | $555.67 | +146.8K | 442.3K | +50% | +$81.58M |
| D | 2025-12-11 | 2025-12-09 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | F - Tax | $701.51 | -131.9K | 310.5K | -30% | -$92.51M |
| MI | 2024-06-12 | 2024-06-10 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | G - Gift | $0.00 | -37.9K | 0 | -100% | $0 |
| M | 2024-05-17 | 2024-05-16 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | S - Sale | $972.73 | -50.0K | 788.0K | -6% | -$48.64M |
| M | 2024-05-17 | 2024-05-15 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | S - Sale | $975.87 | -50.0K | 864.8K | -5% | -$48.79M |
| I | 2024-05-01 | 2024-01-02 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | S - Sale | $900.00 | -16.8K | 180.0K | -9% | -$15.16M |
| MI | 2024-05-01 | 2024-04-29 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | G - Gift | $0.00 | -18.1K | 18.1K | -50% | $0 |
| D | 2024-02-20 | 2024-02-15 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | M - OptEx | $399.66 | +172.7K | 925.2K | +23% | +$69.03M |
| D | 2024-02-20 | 2024-02-15 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | F - Tax | $953.83 | -123.6K | 801.6K | -13% | -$117.89M |
| I | 2024-01-04 | 2024-01-02 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | S - Sale | $900.00 | -16.8K | 180.0K | -9% | -$15.16M |
| D | 2023-12-13 | 2023-12-11 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | M - OptEx | — | +25.2K | 765.3K | +3% | — |
| D | 2023-12-13 | 2023-12-11 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, CSO, Bd. Co-COB, Dir | F - Tax | $844.09 | -12.8K | 752.5K | -2% | -$10.84M |
| MI | 2023-03-27 | 2023-03-23 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | S - Sale | $804.26 | -3,656 | 198.9K | -2% | -$2.94M |
| I | 2023-02-08 | 2023-02-06 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | S - Sale | $800.08 | -13.2K | 200.5K | -6% | -$10.55M |
| DM | 2021-12-23 | 2021-12-22 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | M - OptEx | $221.08 | +442.3K | 1.17M | +61% | +$97.78M |
| DM | 2021-12-23 | 2021-12-22 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | F - Tax | $610.04 | -310.1K | 1.02M | -23% | -$189.17M |
| M | 2021-08-17 | 2021-08-13+ | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | S - Sale | $625.29 | -50.0K | 889.8K | -5% | -$31.26M |
| 2021-08-06 | 2021-08-05 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | S - Sale | $600.06 | -50.0K | 937.5K | -5% | -$30.00M | |
| MI | 2021-08-06 | 2021-06-24 | REGN | Regeneron Pharmaceuticals | YANCOPOULOS GEORGE | Pres, Chief Scientific, Dir | G - Gift | $0.00 | 0 | 213.7K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations